AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

Core Insights - AEON Biopharma announced that the preliminary top-line results from the interim analysis of its Phase 2 trial for ABP-450 in chronic migraine treatment did not meet the primary endpoint [1][2] - The primary endpoint was the mean reduction in monthly migraine days (MMD), which showed a reduction of 8.5 days in the 150 U arm and 7.7 days in the 195 U arm, compared to 8.4 days in the placebo arm, with none achieving statistical significance [2] - The company will continue to evaluate the complete dataset and has initiated cash preservation measures while reviewing strategic options [2][3] Company Overview - AEON Biopharma is a clinical-stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450, for various debilitating medical conditions, particularly in the neurosciences market [4] - ABP-450 is the same botulinum toxin complex currently marketed for cosmetic uses under the name Jeuveau by Evolus [4] - The company holds exclusive development and distribution rights for therapeutic indications of ABP-450 in the U.S., Canada, EU, UK, and other territories [4]